BioAge Labs, Inc.
BIOA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$4.99
KIRA · Stoqly’s AI analyst, in plain words
- BioAge Labs, Inc. had $9.0M of revenue in fiscal 2025.
- Its operating margin was −1,031.5%: of every 100 in sales, about −1,031 is left after running the business.
- BioAge Labs, Inc. lost $80.6M in fiscal 2025.
- Free cash flow was −$82.3M in fiscal 2025, −915.5% of revenue.
- BioAge Labs, Inc. has $278M more cash than debt.
Market cap
$224M
P/E
—
Revenue
$9.0M
Net income
−$80.6M
Free cash flow
−$82.3M
Operating margin
−1,031.5%
BioAge Labs, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−896.1%
No. It lost money last year.
Does profit turn into cash?
−915.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What BioAge Labs, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 24, 2026
- Legal name
- BioAge Labs, Inc.
- CIK
- 0001709941
BioAge Labs, Inc. · BIOA
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | — | $0.0M | $9.0M |
| Operating margin | — | — | −1,031.5% |
| Net income | −$63.9M | −$71.1M | −$80.6M |
| Net margin | — | — | −896.1% |
| Diluted EPS | −$38.17 | −$6.63 | −$2.24 |
| Cash | |||
| Cash from operations | −$37.4M | −$51.5M | −$81.6M |
| Capital expenditure | $0.2M | $0.4M | $0.7M |
| Free cash flow | −$37.5M | −$51.9M | −$82.3M |
| FCF margin | — | — | −915.5% |
| Share count change | — | 541.2% | 235.0% |
| Debt and strength | |||
| Cash and short-term investments | $21.6M | $354M | $281M |
| Debt incl. finance leases | $14.2M | $8.5M | $2.6M |
| Shareholders' equity | −$173M | $323M | $272M |
| Current ratio | 0.4x | 12.9x | 14.2x |
| Interest coverage | −6.2x | −33.0x | −133.1x |
| Returns and quality | |||
| Return on equity | — | −95.0% | −27.1% |
| Return on tangible equity | — | −22.0% | −29.6% |
| Piotroski F-score | — | 4 | 3 |
| Altman Z'' | −46.4 | 11.9 | 12.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$7.8M
4 insiders
Of sales under plans
100%
$7.8M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BioAge Labs, Inc. · BIOA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.99 a share, the company is worth $224M.
Source: SEC EDGAR XBRL filings (CIK 0001709941). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.